|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-10
|
|
pubmed:abstractText |
: Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which has been successfully used for the treatment of age-related macular degeneration with choroidal neovascularization. As VEGF is involved in the pathomechanisms of inflammation and endothelial dysfunction the authors used bevacizumab as a last resort treatment in patients with persistent uveitic cystoid macular edema (CME).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0275-004X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
41-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18185136-Adult,
pubmed-meshheading:18185136-Aged,
pubmed-meshheading:18185136-Angiogenesis Inhibitors,
pubmed-meshheading:18185136-Antibodies, Monoclonal,
pubmed-meshheading:18185136-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18185136-Female,
pubmed-meshheading:18185136-Fluorescein Angiography,
pubmed-meshheading:18185136-Humans,
pubmed-meshheading:18185136-Injections,
pubmed-meshheading:18185136-Macular Edema,
pubmed-meshheading:18185136-Male,
pubmed-meshheading:18185136-Middle Aged,
pubmed-meshheading:18185136-Pilot Projects,
pubmed-meshheading:18185136-Retina,
pubmed-meshheading:18185136-Retrospective Studies,
pubmed-meshheading:18185136-Tomography, Optical Coherence,
pubmed-meshheading:18185136-Uveitis,
pubmed-meshheading:18185136-Vascular Endothelial Growth Factor A,
pubmed-meshheading:18185136-Visual Acuity,
pubmed-meshheading:18185136-Vitreous Body
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.
|
|
pubmed:affiliation |
Interdisciplinary Uveitis Center, Department of Ophthalmology, University of Heidelberg, Germany. friederike.mackensen@uveitiszentrum.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
